<DOC>
	<DOC>NCT00349349</DOC>
	<brief_summary>The purpose of this study is to determine whether HuMax-CD20 (ofatumumab) is effective in the treatment of patients failing both fludarabine and alemtuzumab.</brief_summary>
	<brief_title>HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>1. Tumor cell phenotype consistent with BCLL 2. Patients with active BCLL and with an indication for treatment 3. Failing at least one fludarabinecontaining treatment regimen 4. Failing at least one alemtuzumabcontaining treatment regimen 5. ECOG Performance Status of 0, 1, or 2 6. Life expectancy of at least 4 months 1. Previous treatment with alemtuzumab within 6 weeks prior to Visit 2 2. Previous autologous stem cell transplantation within 6 months prior to Visit 2 3. Allogeneic stem cell transplantation 4. Radioimmunotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>